Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi-Aventis Gets FDA Response for Rimonabant | Contract Pharma

What are you searching for?

Sign in

Sanofi-Aventis Gets FDA Response for Rimonabant

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-Aventis has received an approvable letter from the FDA’s Division of Metabolism and Endocrinology Products for rimonabant for weight management, and a non-approvable letter from the Division of Anesthesia, Analgesia and Rheumathology Products, for smoking cessation. Sanofi-Aventis will continue to work closely with the FDA. Rimonabant is the first in a new class of therapeutic agents called CB(1) blockers.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters